Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892736 · ClinicalTrials.gov registry record · Phase 1
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT00892736: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00892736 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892736, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-04-20 |
| Est. Completion | 2017-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892736
The ClinicalTrials.gov registry entry for NCT00892736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00892736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00892736 about?
NCT00892736 is a clinical study titled "Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy". This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00892736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2009-04-20. Estimated completion is 2017-05-19.
What interventions are being tested in trial NCT00892736?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Veliparib (DRUG).
Who is sponsoring clinical trial NCT00892736?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.